Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease
D.H.F. Gommans*, J. Nas, S.J. Pinto-Sietsma, Y. Koop, R.E. Konst, F. Mensink, G.W.A. Aarts, L.S.F. Konijnenberg, K. Cortenbach, D.V.M. Verhaert, J. Thannhauser, J.Q. Mol, M.J.P. Rooijakkers, J.L. Vos, A. van Rumund, P. Vart, R.J. Hassing, J.H. Cornel, C.P.C. de Jager, M.M. van den HeuvelH.G. van der Hoeven, A. Verbon, Y.M. Pinto, N. van Royen, R.R.J. van Kimmenade, P.W. de Leeuw, M.A. van Agtmael, P. Bresser, W.H. van Gilst, A. Vonk-Noordergraaf, J.G.P. Tijssen, Data Safety Monitoring Board, Event Committee, Steering Comm
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease'. Together they form a unique fingerprint.